Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study
1 other identifier
observational
1,000
1 country
41
Brief Summary
The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China. It is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) who are receiving treatment with faricimab.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Typical duration for all trials
41 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 9, 2024
CompletedFirst Submitted
Initial submission to the registry
May 28, 2024
CompletedFirst Posted
Study publicly available on registry
June 3, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 15, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 15, 2027
May 12, 2026
May 1, 2026
2.5 years
May 28, 2024
May 11, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Visual Acuity from Baseline at Month 12
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Baseline and Month 12
Secondary Outcomes (14)
Visual Acuity Over Time
Baseline, Months 3, 6, 9, 12, 18, and 24
Change in Visual Acuity from Baseline Over Time
Baseline, Months 3, 6, 9, 18, and 24
Central Subfield Thickness Over Time
Baseline, Months 3, 6, 9, 12, 18, and 24
Change in Central Subfield Thickness from Baseline Over Time
Baseline, Months 3, 6, 9, 12, 18, and 24
Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other)
From Baseline to Month 24
- +9 more secondary outcomes
Study Arms (3)
Cohort 1: Patients with nAMD
Cohort 2: Patients with DME
Cohort 3: Patients with RVO
Interventions
The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
Eligibility Criteria
The study will recruit patients who are naĂ¯ve to anti-VEGF therapy in the study eye and those who have previously been treated with anti-VEGF therapy in the study eye. Study participation of patients previously treated with other anti-VEGF agents will be capped at a maximum of 40% of each indication enrollment.
You may qualify if:
- Have signed the informed consent
- Female and male Chinese patients, who had been diagnosed with nAMD, DME, or RVO by CFP, OCT, FFA, ICGA, or OCTA
- ≥50 years old for patients with nAMD, ≥18 years old both for patients with DME and RVO, at the time of signing informed consent (or the first administration of faricimab, whichever occurs first)
- Patients for whom the decision to receive treatment with faricimab is made prior to and independent from study participation
- Patients have received at least one faricimab treatment (the first dose) in the study eye
You may not qualify if:
- Patients not receiving treatment for nAMD/DME/RVO with faricimab according to the standard of care and in line with the current summary of product characteristics (SPC) / labeling in China
- Active ocular inflammation or suspected / active ocular infection in either eye
- Received any other anti-VEGF treatment after faricimab
- Received any steroid treatment within 6 months (180 days) before the first faricimab treatment in the study eye
- Any participation in any other clinical trials currently
- Patients could not provide the clinical data (visual acuity and OCT images) within 2 weeks (14 days) before receiving the initial faricimab injection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hoffmann-La Rochelead
- Shanghai Roche Pharmaceutical Co., Ltdcollaborator
Study Sites (41)
Joint Shantou International Eye Center
Shantou, Guangdong, 515051, China
The First Affiliated Hospital of Henan UN of Science and Technology
Luoyang, Henan, 471000, China
Taihe Hospital of Shiyan
Shiyan, Hubei, 442000, China
Xuzhou No.1 Peoples Hospital
Xuzhou, Jiangsu, 221002, China
Fushun Eye Hospital
Fushun, Liaoning, 110114, China
Panjin Central Hospital
Panjin, Liaoning, 124010, China
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
Affiliated Hospital of Shandong Second Medical University
Weifang, Shandong, 261031, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
The First People's Hospital of Chengdu
Chengdu, Sichuan, 610016, China
The First People's Hospital of Kashgar
Kashgar, Xinjiang Uygur, 844000, China
The First People's Hospital of Yunnan Province
Kunming, Yun'nan, 650032, China
Jinhua municipal central hospital
Jinhua, Zhejiang, 321083, China
Peking University People's Hospital
Beijing, 100044, China
Sichuan Provincial People's Hospital
Chengdu, 610072, China
People's Hospital of Dingzhou
Dingzhou, 73000, China
Dongyang People's Hospital
Dongyang, 322100, China
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, 510060, China
Guizhou Provincial People's Hospital
Guiyang, 550002, China
Eye Hospital of Shandong First Medical University
Jinan, 250021, China
The First Affiliated Hospital of Lanzhou University
Lanzhou, 730000, China
The Affiliated Hospital of Southwest Medical University, Zhongshan Campus
Luzhou, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, 210029, China
The People?s Hospital of Guangxi Zhuang Autonomous Region
Nanning, 530021, China
Qingdao Eye Hospital of Shandong First Medical University
Qingdao, 265299, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, 200025, China
Shanghai Tenth People's Hospital
Shanghai, 200072, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, 200092, China
Shanghai Zhoupu Hospital
Shanghai, China
Shenyang Fourth People's Hospital
Shenyang, 110031, China
Shenzhen Eye Hospital
Shenzhen, 518040, China
Hebei People's Hospital
Shijiazhuang, 050071, China
Shanxi Bethune Hospital
Taiyuan, 030032, China
Tianjin Eye Hospital
Tianjin, 300050, China
Eye Hospital, Wenzhou Medical University
Wenzhou, 325027, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, 430022, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430030, China
Xiamen Eye Center Of Xiamen University
Xiamen, 361000, China
Hebei Eye Hospital
Xingtai, China
Henan Provincial Eye Hosptial
Zhengzhou, 450003, China
Affiliated Hospital of Zunyi Medical University
Zunyi, 563000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 28, 2024
First Posted
June 3, 2024
Study Start
May 9, 2024
Primary Completion (Estimated)
November 15, 2026
Study Completion (Estimated)
November 15, 2027
Last Updated
May 12, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share